진시스템
Financials
Valuation Metrics
진시스템's Market Cap is ₩386B. At end of 2025 it was ₩349B. Ranked #1906 of 2,436 in KR market (top 78%), #1188 of 1,649 on KOSDAQ (top 72%), #206 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 88%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 38.63B KRW | KR#1,906/2,436 Sec#206/234 |
| Revenue | 647.1M KRW | KR#2,395/2,436 Sec#222/234 |
| Net Income | -14.29B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 15.65B KRW | KR#2,376/2,436 Sec#229/234 |
| Net Assets | 9.40B KRW | KR#2,371/2,436 Sec#228/234 |
| Employees | 69 | KR#1,867/2,436 Sec#160/234 |
| Value | ||
| P/B | 4.11x | KR#2,203/2,436 Sec#181/234 |
| P/S | 59.70x | KR#2,373/2,436 Sec#199/234 |
| FCF Yield | -18.39% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -151.93% | KR#2,364/2,436 Sec#223/234 |
| ROA | -91.27% | KR#2,382/2,436 Sec#229/234 |
| Op. Margin | -1440.06% | KR#2,391/2,436 Sec#219/234 |
| Revenue Growth | 419.00% | KR#27/2,436 Sec#7/234 |
| Financial Health | ||
| Debt Ratio | 166.46% | KR#1,392/2,436 Sec#158/234 |
| Total Debt | 3.74B KRW | KR#1,827/2,436 Sec#176/234 |
| FCF | -7.10B KRW | KR#1,601/2,436 Sec#132/234 |
| Cash | 4.35B KRW | KR#2,049/2,436 Sec#186/234 |
| Current Ratio | 2.62x | KR#705/2,436 Sec#88/234 |
| Performance | ||
| 1Y Return | -17.45% | KR#1,194/2,436 Sec#94/234 |
| 1M Return | 39.48% | KR#42/2,436 Sec#2/234 |
| From 52W High | -37.47% | KR#655/2,436 Sec#45/234 |
| 1Y MDD | -65.89% | KR#1,744/2,436 Sec#146/234 |
| Trading | ||
| Volume | 16,158 shares | KR#1,952/2,436 Sec#194/234 |
| Foreign Own. | 2.31% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | -1,645 KRW | KR—/2,436 Sec—/234 |
| BPS | 1,262 KRW | KR#2,224/2,436 Sec#197/234 |
Company Info
GeneSystem was established in 2010 to commercialize a rapid PCR technology-based platform and was listed on KOSDAQ in 2021. The company specializes in molecular diagnostic equipment and diagnostic kits, expanding its business primarily in Europe and Asia, and experienced growth in developing country markets post-2020 pandemic. It pursues market entry by diversifying rapid platform technology-based testing solutions and employing a two-track B2B strategy, continuously releasing respiratory disease diagnostic content for the post-COVID era to drive global market adoption. Headquartered in Yuseong-gu, Daejeon, GeneSystem was founded in 2010.